000			03834nam a22004217a 4500
008			240807s20222022 xxu||||| |||| 00| 0 eng d
022			_a2218-6778
024			_aPMC11093008 [pmc]
024			_atbcr-03-37 [pii]
040			_aOvid MEDLINE(R)
099			_a38751533
245			_aRisk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review.
251			_aTranslational Breast Cancer Research : A Journal Focusing on Translational Research in Breast Cancer. 3:37, 2022.
252			_aTransl Breast Cancer Res. 3:37, 2022.
253			_aTranslational breast cancer research : a journal focusing on translational research in breast cancer
260			_c2022
260			_p2022
265			_sepublish
265			_tPubMed-not-MEDLINE
266			_d2024-08-07
266			_z2024/05/16 03:36
520			_aBackground: Inherited germline mutations in PALB2 are known to predispose patients to a higher risk of breast, ovarian and pancreatic cancer with an estimated risk of developing breast cancer in over half of all affected women by age 80 years. Current guidelines for screening patients with PALB2 mutations include annual mammograms beginning at age 30 years and consideration of breast magnetic resonance imaging (MRI) and tomosynthesis. Existing evidence regarding risk-reducing surgery with mastectomy is insufficient to make a definitive recommendation to patients. In this case series, we describe the presentation and management of 5 patients with unilateral breast cancer and PALB2 mutations. To our knowledge, this is the first reported case series discussing the role of contralateral risk-reducing mastectomy (CRRM) in breast cancer patients with PALB2 mutations. The aim of our study was to evaluate the challenges in managing breast cancer risk in patients with PALB2 pathogenic variants with illustration through real-world clinical cases and a review of the literature.
520			_aConclusions: Based on our experience and the currently available literature, CRRM in patients with a PALB2 mutation should be performed on a case-by-case basis through a shared decision-making process taking into consideration overall risk, family history, patient preference and quality of life. Copyright 2022 Translational Breast Cancer Research. All rights reserved.
520			_aMethods: In this retrospective observational study, we present 5 patients with PALB2 mutations between the ages of 29 and 61 years who were diagnosed with breast cancer and underwent surgical management of their breast cancer at our institution between November 2020 and March 2022. Through their clinical courses and a literature review, we discuss the role of CRRM in breast cancer patients with PALB2 gene mutations.
520			_aResults: Out of the 5 patients, 3 patients underwent CRRM and 2 patients chose unilateral surgery for their breast cancer and active surveillance for the contralateral breast. Of the 3 patients who underwent CRRM, 1 patient experienced a surgical complication from reconstruction on the prophylactic side. None of the patients developed any recurrences with an average length of follow up of 15.4 months.
546			_aEnglish
650			_zAutomated
656			_aMedStar General Surgery Residency
656			_aMedStar Georgetown University Hospital/MedStar Washington Hospital Center
656			_aSurgery
657			_aJournal Article
700			_aBoisvert, Marc _bMWHC
700			_aMasanam, Monika _bMGUH _cMedStar General Surgery Residency _dMD
700			_aStarks, Leah _bMGUH _cMedStar General Surgery Residency _dMD
790			_aMasanam MK, Pitcher CW, Sogunro O, Starks LK, Murray AB, Boisvert ME
856			_uhttps://dx.doi.org/10.21037/tbcr-22-33 _zhttps://dx.doi.org/10.21037/tbcr-22-33
942			_cART _dArticle
999			_c14504 _d14504